Phylloceuticals
Phylloceuticals uses a plant-made technology that offers lower overall investment and enhances the world’s ability to supply biologics to all populations.
Latest Content
Product News
Phylloceuticals Produces First Plant-Based PD-1 Inhibitor
Phylloceuticals has produced its first plant-based PD-1 inhibitor monoclonal antibody only 12 weeks after launching operations in Rapid City, SD.
Product News
Phylloceuticals Appoints Biotech Veteran Nick Casale to Board of Directors
Phylloceuticals has appointed Nick Casale to its Board of Directors. With over 30 years in biotech engineering and operations, Casale brings expertise from roles at Ultragenyx, Novartis, Biogen and more.
Industry Insight
Time To Shine: Photosynthetic Biotech Is Ripe for the Picking
Renewed efforts to tap cyanobacteria, algae and plants in arenas typically dominated by heterotrophic systems are already beginning to yield fruit. In this article, we explore the inherent value of photosynthetic biotechnologies and their challenges.
Industry Insight
What’s on the Horizon for Clinical Trials in 2023?
From increasing trial diversity to using plants to manufacture drugs, the experts weigh in.
Industry Insight
Failing Fast at the Forefront of Innovation for Pharma Companies
In this article, we explore how equipment, laboratory and experimental approaches can accelerate failure so companies change and adjust their approach before it’s too late.
Industry Insight
Developing a Sustainable Source of Squalene
Technology Networks spoke to Jason Ornstein and Barry Holtz to learn how Synshark and Phylloceuticals are working together to address current challenges associated with squalene supply and access.
Advertisement
